|
시장보고서
상품코드
2076209
C형 간염 치료제 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Hepatitis C Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
C형 간염 치료제 시장은 2026년에 103억 달러로 추정되고 있으며, 2033년에 140억 2,000만 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 4.5%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 103억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 4.50% | 2033년 시장 규모 예측 : | 140억 2,000만 달러 |
C형 간염은 심각한 간 손상을 일으킬 수 있는 간 감염증입니다. C형 간염 바이러스에 의해 발생합니다. 미국에서는 약 240만 명이 이 병에 걸려 있습니다. 그러나 증상이 거의 나타나지 않기 때문에 대다수는 이를 자각하지 못하고 있습니다. 이 바이러스는 감염자의 혈액이나 체액을 통해 전파됩니다.
C형 간염의 병기: 잠복기. 이는 바이러스에 처음 노출된 후 증상이 나타나기까지의 기간입니다. 14일부터 80일까지 폭이 있지만, 평균은 45일입니다. 급성 C형 간염. 이는 바이러스가 체내에 침입한 후 처음 6개월 동안 지속되는 단기적인 질병입니다. 그 후, 감염자 중에는 체내에서 자연적으로 바이러스를 제거(클리어)하는 사람도 있습니다. 만성 C형 간염. C형 간염에 감염된 사람의 대다수(최대 85%)는 증상이 장기화되는 단계(6개월 이상)로 접어듭니다. 이것은 '만성 C형 간염'이라고 불리며, 간암이나 간경변과 같은 심각한 건강 문제를 일으킬 가능성이 있습니다. 간경변. 이 질환은 염증을 유발하며, 시간이 지남에 따라 건강한 간세포가 흉터 조직으로 대체됩니다. 일반적으로 이 과정에는 약 20년 30년이 걸리지만, 알코올을 섭취하거나 HIV에 감염된 경우에는 진행 속도가 빨라질 수 있습니다.
시장 역학
전 세계에서 C형 간염 유병률이 증가하고 있는 것이 예측 기간 중 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어 2021년 9월 18일 미국 국립생물공학정보센터(NCBI)가 발표한 자료에 따르면 인도의 HCV 유병률은 0.5%이며, 약 470만-1,090만 명이 이 질환을 앓고 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 C형 간염 치료제 시장 : 약제 클래스별, 2021-2033년
제5장 C형 간염 치료제 시장 : 투여 경로별, 2021-2033년
제6장 C형 간염 치료제 시장 : 유통 채널별, 2021-2033년
제7장 C형 간염 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.07.09Hepatitis C Drugs Market is estimated to be valued at USD 10.30 Bn in 2026 and is expected to reach USD 14.02 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.30 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.50% | 2033 Value Projection: | USD 14.02 Bn |
Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.
Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.
Market Dynamics:
The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.
Hepatitis C Drugs Market Segmentation:
- By Drug Class (Revenue, USD Bn, 2021 - 2033)
- NS3/4A Protease Inhibitors
- NS5A Inhibitors
- NS5B Polymerase Inhibitors
- Combination Drugs
- Others
- By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral Drugs
- Intravenous
- Others
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in Hepatitis C Drugs Market:
- Gilead Sciences
- AbbVie
- Merck & Co
- Bristol-Myers Squibb
- Johnson & Johnson
- Hoffmann-La Roche AG
- Boehringer Ingelheim
- Achillion Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Growing Prevalence of Hepatitis C Globally
- Increasing Government Initiatives
- Restraints
- Increasing Adverse Effects
- Opportunities
- Increasing Product Availability in Various Regions
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Hepatitis C Drugs Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- NS3/4A Protease Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- NS5B Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Combination Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
5. Hepatitis C Drugs Market, By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Oral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
6. Hepatitis C Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
7. Hepatitis C Drugs Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2023and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- China
- Japan
- India
- Australia
- ASEAN
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Achillion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
